Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL7102233 | 0.92 | ADORA2A (0.42) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7104803 | 0.91 | ADORA3 (0.42) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7208768 | 0.87 | ADORA2A (0.40) | ADORA2AADORA2BADORA3 | |
| SCHEMBL7102237 | 0.81 | CCNA2 (0.38) | ADORA2AADORA2BADORA3ADORA1 | |
| Formic Acid SCHEMBL7208762 | 0.79 | ADORA2A (0.43) | ADORA2AADORA2BADORA3 | |
| SCHEMBL7207666 | 0.78 | ADORA2A (0.42) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7566399 | 0.78 | ADORA2A (0.41) | ADORA2AADORA2BADORA1 | |
| SCHEMBL7099680 | 0.76 | ADORA1 (0.57) | ADORA2AADORA2BADORA3ADORA1TMIGD3 | |
| SCHEMBL7151509 | 0.75 | ADORA2A (0.43) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7104801 | 0.75 | ADORA2A (0.43) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090023-B1 | 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-09-10 | — | — | EP | disclosed |